Your browser doesn't support javascript.
loading
The 5HT2b Receptor in Alzheimer's Disease: Increased Levels in Patient Brains and Antagonist Attenuation of Amyloid and Tau Induced Dysfunction.
Acquarone, Erica; Argyrousi, Elentina K; Arancio, Ottavio; Watterson, D Martin; Roy, Saktimayee M.
Afiliación
  • Acquarone E; Taub Institute for Research on Alzheimer's Disease and the Aging Brain, New York, NY, USA.
  • Argyrousi EK; Taub Institute for Research on Alzheimer's Disease and the Aging Brain, New York, NY, USA.
  • Arancio O; Taub Institute for Research on Alzheimer's Disease and the Aging Brain, New York, NY, USA.
  • Watterson DM; Department of Internal Medicine, Columbia University, New York, NY, USA.
  • Roy SM; Department of Pathology and Cell Biology, Columbia University, New York, NY, USA.
J Alzheimers Dis ; 98(4): 1349-1360, 2024.
Article en En | MEDLINE | ID: mdl-38578894
ABSTRACT

BACKGROUND:

Background:

Neurodegenerative diseases manifest behavioral dysfunction with disease progression. Intervention with neuropsychiatric drugs is part of most multi-drug treatment paradigms. However, only a fraction of patients responds to the treatments and those responding must deal with drug-drug interactions and tolerance issues generally attributed to off-target activities. Recent efforts have focused on the identification of underexplored targets and exploration of improved outcomes by treatment with selective molecular probes.

Objective:

As part of ongoing efforts to identify and validate additional targets amenable to therapeutic intervention, we examined levels of the serotonin 5-HT2b receptor (5-HT2bR) in Alzheimer's disease (AD) brains and the potential of a selective 5-HT2bR antagonist to counteract synaptic plasticity and memory damage induced by AD-related proteins, amyloid-ß, and tau.

Methods:

This work used a combination of biochemical, chemical biology, electrophysiological, and behavioral techniques. Biochemical methods included analysis of protein levels. Chemical biology methods included the use of an in vivo molecular probe MW071, a selective antagonist for the 5HT2bR. Electrophysiological methods included assessment of long-term potentiation (LTP), a type of synaptic plasticity thought to underlie memory formation. Behavioral studies investigated spatial memory and associative memory.

Results:

5HT2bR levels are increased in brain specimens of AD patients compared to controls. 5HT2bR antagonist treatment rescued amyloid-ß and tau oligomer-induced impairment of synaptic plasticity and memory.

Conclusions:

The increased levels of 5HT-2bR in AD patient brains and the attenuation of disease-related synaptic and behavioral dysfunctions by MW071 treatment suggest that the 5HT-2bR is a molecular target worth pursuing as a potential therapeutic target.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedad de Alzheimer Límite: Animals / Humans Idioma: En Revista: J Alzheimers Dis Asunto de la revista: GERIATRIA / NEUROLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Enfermedad de Alzheimer Límite: Animals / Humans Idioma: En Revista: J Alzheimers Dis Asunto de la revista: GERIATRIA / NEUROLOGIA Año: 2024 Tipo del documento: Article País de afiliación: Estados Unidos